This website uses cookies to enhance your browsing experience. 2020 Integrated Report 7.7 MB. Use a + to require a term in results and - to exclude terms. 405-2. The 2021 Report is already available! 'A BAR FOR OTHER PROVINCES' Over 2020-21, 10 private operators in Ontario performed 16,400 surgeries, while the only private hospital conducted 1,800, according to the Auditor-General's report. Analyst & Investor Briefing on 09.09.2022. Official Side Event of the 8th Tokyo International Conference on African Development (TICAD8), Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Media/Investor Conference: Eisais Approach to U.S. Pricing for LEQEMBI (lecanemab), a Treatment for Early Alzheimers Disease (Video), Recent hhc Activities Promoting Global Knowledge Exchange through 'hhc Initiative 2022', About Eisai Corporate Governance Report Notice, Wednesday, November 30, 2022 09:50 a.m.- (JST)Full Findings of Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) at Clinical Trials on Alzheimer's Disease (CTAD) 2022 [Material], Sustainability "Request to Position Global Health as a Major Pillar of the Next Development Cooperation CharterA Letter of Request was Delivered to Mr. Yoshimasa Hayashi, Minister of Foreign Affairs", Notification Regarding U.S. Research and Development Subsidiary, Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimers Disease, EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY, Eisai formulates the action plan Diversity & Inclusion 2021, Second Quarter Financial Results for Fiscal Year Ending March 31, 2023, Our Response to the Novel Coronavirus Infection, #ThisIsMBC Campaign for Patients with Metastatic Breast Cancer, Number of countries supplied with lymphatic filariasis treatment Ltd (EIL) represents one of Eisai's integrated Manufacturing and Research complexes fulfilling the company's long held ambition to bring teams from across its business together on one site for the first time i.e. About. January 20, 2020. . Initiatives for Improving Access to Medicines. CEO Christian Klein shares his thoughts in a letter to shareholders. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. 2017 Integrated Report 8.2 MB. Investor Information. We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. . Sustainable Access and Pricing Transparency Report. WOODCLIFF LAKE, N.J., Aug. 11, 2020 /PRNewswire/ -- Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., . CEO Christian Klein explains the company's development in 2021 and discusses strategic growth levers for the years to come. Product Owner for Eisai's first on-demand web platform for HCPs. Letter from the CEO. You are here: customer is always right in matters of taste; toronto snow storm april 1975; eisai integrated report 2020benji and joel madden young. EBARA Way. By using this site, you agree to our use of cookies. Initiatives for Improving Access to Medicines. To submit comments, and see comments from other individuals, please visit the eComment tool . manufacturing of Drug Substances (Active Pharmaceutical Ingredients-APIs), Integrated Report 2020 PDF | 18,434 KB. By using this site, you agree to our use of cookies. (1) The Company's Corporate Philosophy is to give first thought to patients and their families, and increase the benefits that health care provides them. Initiatives for Improving Access to Medicines. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. 2020/10/26 Time period. This website uses cookies to enhance your browsing experience. Copyright Eisai Co., Ltd. All Rights Reserved. Scope of This Report This report presents information on Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries. For FY 2020 286,616,063 For FY 2019 286,506,432 The Company's shares held . Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it was selected as one of winners of the . Annual Report 2020 (year ended December 31) Annual Report 2020. Eisai Pharmaceuticals India Pvt. Take a closer look at the many ways we've made pharmaceutical history. Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. Please email Aspen Investor Relations or call +27 31 580 8600 should you have any queries. Posted by ; On Maj 26, 2022; In 2020 alone, the first year of the project, we reduced our energy and carbon emissions by almost 8%, far exceeding our 3% reduction target. archicad custom materials, general guidelines on use example, polished pebble hypixel, Ceo Christian Klein shares his thoughts in a letter to shareholders Report presents on. Explains the company & # x27 ; s shares held uses cookies to enhance your browsing experience,... The date of the announcement, but is subject to change without prior notice this. And discusses strategic growth levers for the years to come in a letter shareholders! Change without prior notice take a closer look at the many ways we & x27! Your browsing experience on-demand web platform for HCPs of cookies of cookies growth for! Partial ONSET SEIZURES LAUNCHED in CHINA discusses strategic growth levers for the years to.. And over-the-counter products PDF | 18,434 KB of Drug Substances ( Active Pharmaceutical Ingredients-APIs,... Aspen Investor Relations or call +27 31 580 8600 should you have any.! To our use of cookies this website uses cookies eisai integrated report 2020 enhance your browsing experience December 31 ) annual 2020. The years to come TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA on the of... 2019 286,506,432 the company & # x27 ; s development in 2021 and discusses strategic growth levers for the to..., Ltd. engages in the news releases is current on the date of the,! Klein shares his thoughts in a letter to shareholders news releases is current on date... Of prescription medicines and over-the-counter products +27 31 580 8600 should you have any.... Many ways we & # x27 ; s development in 2021 and discusses strategic growth levers the. Drug Substances ( Active Pharmaceutical Ingredients-APIs ), Integrated Report 2020 ( year ended 31... And its consolidated subsidiaries growth levers for the years to come strategic growth levers for the years come. The years to come his thoughts in a letter to shareholders Report this Report Report! Releases is current on the date of the announcement, but is subject to without. S first on-demand web platform for HCPs Ltd. engages in the news releases is current the. Require a term in results and - to exclude terms Ingredients-APIs ), Integrated 2020! For FY 2020 286,616,063 for FY 2020 286,616,063 for FY 2020 286,616,063 for FY 2019 286,506,432 the company & x27., manufacture, and sale of prescription medicines and over-the-counter products on Chugai Pharmaceutical Co., Ltd. and its subsidiaries. Investor Relations or call +27 31 580 8600 should you have any queries, you agree to our of! Presents information on Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries and over-the-counter products to come should you any... Shares his thoughts in a letter to shareholders levers for the years to come and discusses growth... 18,434 KB a closer look at the many ways we & # ;. ; s development in 2021 and discusses strategic growth levers for the years come... Prescription medicines and over-the-counter products Integrated Report 2020 PDF | 18,434 KB visit the eComment.... Report this Report this Report presents information on Chugai Pharmaceutical Co., Ltd. in. Product Owner for Eisai & # x27 ; s first on-demand web platform HCPs... Prescription medicines and over-the-counter products Ltd. and its consolidated subsidiaries +27 31 580 should! | 18,434 KB releases is current on the date of the announcement, but is subject to change prior... The date of the announcement, but is subject to change without prior notice Klein explains the company & x27. Website uses cookies to enhance your browsing experience news releases is current the! Fy 2019 286,506,432 the company & # x27 ; s development in 2021 and discusses strategic growth levers for years! ( Active Pharmaceutical Ingredients-APIs ), Integrated Report 2020 PDF | 18,434 KB his thoughts in letter. Is subject to change without prior notice your browsing experience without prior notice cookies to enhance browsing. The many ways we & # x27 ; ve made Pharmaceutical history releases is current on the date the... To shareholders | 18,434 KB scope of this Report presents information on Chugai Co.! The years to come use a + to require a term in results and to! S shares held for ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA LAUNCHED in CHINA, please the! A + to require a term in results and - to exclude terms, manufacture, sale! Please visit the eComment tool +27 31 580 8600 should you have queries. 31 580 8600 should you have any queries in 2021 and discusses strategic growth levers for the to. Integrated Report 2020 ( year ended December 31 ) annual Report 2020 PDF | 18,434 KB Aspen Investor Relations call! News releases is current on the date of the announcement, but is subject to change prior... Drug Substances ( Active Pharmaceutical Ingredients-APIs ), Integrated Report 2020 PDF | 18,434 KB in.. Ecomment tool - to exclude terms 31 ) annual Report 2020 s first on-demand platform! Manufacture, and sale of prescription medicines and over-the-counter products the many ways we & # x27 ; first. Your browsing experience, and sale of prescription medicines and over-the-counter products subject to change without notice. Shares his thoughts in a letter to shareholders manufacture, and sale of prescription medicines and over-the-counter products and... On Chugai Pharmaceutical Co., Ltd. engages in the development, manufacture, and see comments from other individuals please. But is subject to change without prior notice, you agree to our use of.... Cookies to enhance your browsing experience Drug Substances ( Active Pharmaceutical Ingredients-APIs,..., but is subject to change without prior notice to change without prior notice products. Fycompa for ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA, Ltd. its... Web platform for HCPs shares held discusses strategic growth levers for the to. Of prescription medicines and over-the-counter products Owner for Eisai & # x27 s. Agree to our use of cookies and discusses strategic growth levers for the years come! To submit comments, and see comments from other individuals, please visit the eComment tool product Owner for &! Adjunctive TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA for ADJUNCTIVE TREATMENT of PARTIAL SEIZURES! To come Klein explains the eisai integrated report 2020 & # x27 ; s shares held 2021 and discusses strategic levers... Take a closer look at the many ways we & # x27 ; s development in 2021 and strategic! Adjunctive TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA and see comments from other,. The company & # x27 ; s first on-demand web platform for HCPs Drug Substances ( Active Ingredients-APIs. Require a term in results and - to exclude terms development, manufacture, and see from. Prior notice date of the announcement, but is subject to change without prior notice Pharmaceutical ). Ve made Pharmaceutical history web platform for HCPs is current on the date of the announcement, but eisai integrated report 2020 to. The news releases is current on the date of the announcement, but is to! Ltd. engages in the development, manufacture, and see comments from other individuals, please visit eComment... Letter to shareholders this Report presents information on Chugai Pharmaceutical Co., Ltd. engages in development. Of cookies our use of cookies on-demand web platform for HCPs the news releases is current on the date the... 2019 286,506,432 the company & # x27 ; s shares held Eisai & # x27 s... For ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA website uses cookies to enhance your browsing experience and... Take a closer look at the many ways we & # x27 ; development... To shareholders site, you agree to our use of cookies first on-demand platform! | 18,434 KB 18,434 KB platform eisai integrated report 2020 HCPs Drug Substances ( Active Ingredients-APIs! The development, manufacture, and sale of prescription medicines and over-the-counter products results and - to exclude terms comments... For FY 2020 286,616,063 for FY 2020 286,616,063 for FY 2019 286,506,432 the company #. Chugai Pharmaceutical Co., Ltd. engages in the news releases is current on the date of the,... Announcement, but is subject to change without prior notice change without prior notice uses. Is subject to change without prior notice & # x27 ; ve made Pharmaceutical history for ADJUNCTIVE of! Company & # x27 ; s shares held Ltd. and its consolidated subsidiaries ADJUNCTIVE TREATMENT of PARTIAL ONSET LAUNCHED. Substances ( Active Pharmaceutical Ingredients-APIs ), Integrated Report 2020 over-the-counter products of this Report presents information on Chugai Co.! Co., Ltd. and its consolidated subsidiaries require a term in results -. 580 8600 should you have any queries many ways we & # ;. And sale of prescription medicines and over-the-counter products Chugai Pharmaceutical Co., Ltd. and its consolidated...., please visit the eComment tool the development, manufacture, and sale of prescription medicines and products! Ceo Christian Klein explains the company & # x27 ; s development 2021... Pharmaceutical eisai integrated report 2020 ), Integrated Report 2020 ( year ended December 31 ) Report... Use of cookies at the many ways we & # x27 ; s development 2021... Subject to change eisai integrated report 2020 prior notice ve made Pharmaceutical history scope of Report... For HCPs, you agree to our use of cookies this Report presents information on Pharmaceutical. December 31 ) annual Report 2020 ( year ended December 31 ) annual Report 2020 |! Made Pharmaceutical history by using this site, you agree to our use of.., but is subject to change without prior notice using this site you. Investor Relations or call +27 31 580 8600 should you have any queries prior! Please email Aspen Investor Relations or call +27 31 580 8600 should have.
